405 research outputs found
The ipilimumab lesson in melanoma: Achieving long-term survival
No full textThe anti-cytotoxic T-lymphocyte antigen-4 (anti CTLA-4) antibody ipilimumab is the first treatment that significantly improved the survival rates of metastatic melanoma patients, marking a new era in the treatment of melanoma. During its development, a hallmark of ipilimumab therapy was the extended duration of response, achieved in 20% of patients. The follow-up of patients included in phase II and phase III trials and in expanded access programs revealed that the survival rates remained stable after 3 years. These results demonstrated that ipilimumab induces an effective anti-tumor immune response persisting after the completion of treatment, and suggested a potential remission in a subset of patients. In this article we review the development of ipilimumab and highlight the long-term results. This approach emphasizes the need to optimize the use of ipilimumab in the future, by identifying the patients most likely to achieve long term survival after ipilimumab therapy, and by developing combined therapeutic approaches involving cytotoxic agents, targeted therapies or other immunotherapies to achieve durable control in a larger proportion of patients. (C) 2015 Elsevier Inc. All rights reserved
Soetens (C.) Recueil des archives Vincent Lebbe. La Règle des Petits Frères de Saint-Jean- Baptiste
No full textSéguy Jean. Soetens (C.) Recueil des archives Vincent Lebbe. La Règle des Petits Frères de Saint-Jean- Baptiste. In: Archives de sciences sociales des religions, n°64/2, 1987. p. 332
Soetens (C.) Recueil des archives Vincent Lebbe. La Règle des Petits Frères de Saint-Jean- Baptiste
No full textSéguy Jean. Soetens (C.) Recueil des archives Vincent Lebbe. La Règle des Petits Frères de Saint-Jean- Baptiste. In: Archives de sciences sociales des religions, n°64/2, 1987. p. 332
雷鳴遠 [Vincent Lebbe] : Chinois parmi les Chinois
No full textDans la continuité de récits portant sur des destins exceptionnels liés à Tianjin tels que celui de Grace Liu qui avait fait l'objet d'un précédent article, c'est le parcours et le rôle profondément atypiques d'un autre personnage qui ont inspiré l'écriture du présent billet. Cette présentation s'appuie en grande partie sur le documentaire "Lei Ming Yuan [Vincent Lebbe] : Le tonnerre qui chante au loin - Chinois parmi les Chinois" que l'on peut regarder en ligne. Vincent Lebbe, de son nom c..
HEALTH-CARE RESOURCE UTILIZATION IN ADVANCED MELANOMA: AN ANALYSIS FROM THE MELODY OBSERVATIONAL STUDY
No full textOBJECTIVES: We conducted this study to document the health-care resource utilization associated with treatment of patients with advanced melanoma. METHODS: MELODY (Melanoma treatment patterns and outcomes among patients with unresectable stage III or stage IV disease: a retrospective longitudinal survey) is an observational study managed at 31 centers in France, Italy, and the UK. Eligible patients had attended at one of the sites with a diagnosis of unresectable stage III or IV melanoma between July 1, 2005 and June 30, 2006; data were retrieved from diagnosis (no limit date) until 2008. The primary objective was to document the first-line treatments received by patients. Secondary objectives included ascertaining health-care resource utilization related to up to three lines of treatment (anticancer and supportive care). Data were collected from patients (n = 776) using a case-report form that included information on hospitalizations, outpatient visits, hospice care, and adverse- event management (transfusions and concomitant medications including antiemetics and growth factors). Resource use data were collected from patients (n = 606) that received systemic treatment outside a clinical trial and/or supportive care. RESULTS: Twenty-nine percent (176/606) of patients required medical management for treatment-related adverse events and 32% (195/606) were hospitalized while receiving systemic treatment and/or supportive care with 25% of these having at least four hospitalizations. The median duration of hospitalization was 17 days, with 25% spending at least 29 days in hospital (may comprise multiple stays). The hospitaliza- tion rate was higher in patients receiving supportive care than those receiving anticancer treatment (86/170; 51% vs. 140/553; 25%), but median duration of hospitalization was similar (15.0 vs. 14.5 days). Results by line of anticancer therapy and supportive care will be presented. CONCLUSIONS: These results from MELODY suggest that the systemic and palliative treatments used to manage advanced melanoma are associated with considerable resource utilization, highlighting the need for more effective treatment options
Phase 3 Randomized Study of Ipilimumab (IPI) Plus Dacarbazine (DTIC) Vs DTIC Alone as First Line Treatment in Patients With Unresectable Stage III or IV Melanoma
No full text- …
